ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Interaction of CSF α-synuclein and amyloid beta in cognition and cortical atrophy.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 7 citations in OpenAlex.
- Polymeric lysosome-targeting chimeras for extracellular α-synuclein degradation in Parkinson's disease.Acta neuropathologica communications · 2026Review
- Towards a Biologically Defined Diagnosis: Incorporating Pathophysiological Measures Into Parkinson's Disease Clinical Criteria.Parkinson's disease · 2026Review
- Article
- Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease.Advances in neurobiology · 2023Review
- Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders.Journal of clinical medicine · 2022Article
- Effects of Alzheimer's genetic risk scores and CSF biomarkers in de novo Parkinson's Disease.NPJ Parkinson's disease · 2022Article
- Associations of Polygenic Risk Score for Late-Onset Alzheimer's Disease With Biomarkers.Frontiers in aging neuroscience · 2022Review
- Interaction of CSF α-synuclein and amyloid beta in cognition and cortical atrophy.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
- Atrophy signature for alpha-synuclein copathology in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Erratum issuedErratum.2021
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
introductionLewy body-related pathology is commonly observed at autopsy in individuals with dementia, but in vivo biomarkers for α-synucleinopathy are lacking.
methodsBaseline cerebrospinal fluid (CSF) biomarkers, polygenic risk score (PRS) for Parkinson's disease (PRS-PD) and Alzheimer's disease (PRS-AD), longitudinal cognitive scores, and magnetic resonance imaging were measured in 217 participants from the Alzheimer's Disease Neuroimaging Initiative. Linear mixed models were used to find the relationship of CSF biomarkers and the PRS with cognition and cortical atrophy.
resultsHigher PRS-PD and PRS-AD were associated with lower CSF α-synuclein and amyloid beta (Aβ), respectively. Lower CSF α-synuclein and the interaction of CSF α-synuclein and Aβ were associated with lower cognitive scores and global cortical atrophy most prominently in the occipital cortex. DISCUSSION: Lower CSF α-synuclein could be a biomarker for α-synucleinopathy, and the simultaneous evaluation of CSF biomarkers for AD and CSF α-synuclein could reveal the independent and interactive effects on cognition and cortical atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.